$heff's $tation of $tocks & $olid DD

[hogfan2]

$CYNA...
Jason Napodano, CFAPremium Research »
Research analyst, medium-term horizon, biotech, small-cap
Profile| Send Message| Follow (5,097 followers) Performance
What To Buy Based On The Biotech Pullback
Aug. 24, 2015 10:20 AM ET | 63 comments | Includes: ABBV, ADMA, BLUE, CRBP, CUR, CYNA, JUNO, KITE, NBIX, NVIV, PIRS, POZN, TBUFF, XBI
Disclosure: I am/we are long NVIV, BLUE, JUNO, CUR. (More...)


Cynapsus Therapeutics (NASDAQ:CYNA): Now Nasdaq-listed Cynapsus is another of my top-picks. The company is progressing in its Phase 3 trial with APL-130277 for the acute rescue of OFF motor symptoms of patients with Parkinson's disease (PD-OFF). I think the stock looks like a big potential winner, and I'm not the only one who thinks that to be the case. A lot of really smart healthcare funds are loaded-up in Cynapsus. The major institutional holding list as of June 30, 2015, shows some big players with sizable stakes in the name. My article outlines why I believe APL-130277 is a better option for the treatment of PD-OFF than the current standard of care, subcutaneous apomorphine or its next-nearest competitor, Acorda's inhaled levodopa also in Phase 3 trials. I think APL-130277 has peak U.S. sales potential of nearly $700 million. The company has over $111 million in cash as of June 30 and the current Phase 3 trial, which should offer data next year, looks low-risk / high-reward in my view. I think Cynapsus is worth $30 per share, another potential double.

http://seekingalpha.com/article/3461486-what-to-buy-based-on-the-biotech-pullback?page=2